Early  ||| S:0 E:6 ||| RB
inflammatory  ||| S:6 E:19 ||| JJ
clinics ||| S:19 E:26 ||| NNS
.  ||| S:26 E:28 ||| .
Experience  ||| S:28 E:39 ||| NN
with  ||| S:39 E:44 ||| IN
early  ||| S:44 E:50 ||| JJ
arthritis ||| S:50 E:59 ||| NN
/ ||| S:59 E:60 ||| VBZ
back  ||| S:60 E:65 ||| RB
pain  ||| S:65 E:70 ||| JJ
clinics  ||| S:70 E:78 ||| NNS
There  ||| S:78 E:84 ||| EX
is  ||| S:84 E:87 ||| VBZ
a  ||| S:87 E:89 ||| DT
clear  ||| S:89 E:95 ||| JJ
need  ||| S:95 E:100 ||| NN
to  ||| S:100 E:103 ||| TO
assess  ||| S:103 E:110 ||| VB
patients  ||| S:110 E:119 ||| NNS
presenting  ||| S:119 E:130 ||| VBG
with  ||| S:130 E:135 ||| IN
a  ||| S:135 E:137 ||| DT
new  ||| S:137 E:141 ||| JJ
onset  ||| S:141 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
inflammatory  ||| S:150 E:163 ||| JJ
peripheral  ||| S:163 E:174 ||| JJ
arthritis  ||| S:174 E:184 ||| NN
and ||| S:184 E:187 ||| CC
/ ||| S:187 E:188 ||| NNP
or  ||| S:188 E:191 ||| CC
back  ||| S:191 E:196 ||| RB
pain  ||| S:196 E:201 ||| JJ
early ||| S:201 E:206 ||| JJ
.  ||| S:206 E:208 ||| .
Indeed ||| S:208 E:214 ||| RB
,  ||| S:214 E:216 ||| ,
the  ||| S:216 E:220 ||| DT
clinical  ||| S:220 E:229 ||| JJ
presentation  ||| S:229 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
rheumatoid  ||| S:245 E:256 ||| JJ
arthritis  ||| S:256 E:266 ||| NN
( ||| S:266 E:267 ||| -LRB-
RA ||| S:267 E:269 ||| NNP
)  ||| S:269 E:271 ||| -RRB-
is  ||| S:271 E:274 ||| VBZ
not  ||| S:274 E:278 ||| RB
always  ||| S:278 E:285 ||| RB
characteristic  ||| S:285 E:300 ||| JJ
but  ||| S:300 E:304 ||| CC
its  ||| S:304 E:308 ||| PRP$
early  ||| S:308 E:314 ||| JJ
diagnosis  ||| S:314 E:324 ||| NN
is  ||| S:324 E:327 ||| VBZ
crucial  ||| S:327 E:335 ||| JJ
to  ||| S:335 E:338 ||| TO
prevent  ||| S:338 E:346 ||| VB
irreversible  ||| S:346 E:359 ||| JJ
structural  ||| S:359 E:370 ||| JJ
damage ||| S:370 E:376 ||| NN
.  ||| S:376 E:378 ||| .
Likewise  ||| S:378 E:387 ||| RB
low  ||| S:387 E:391 ||| JJ
back  ||| S:391 E:396 ||| JJ
pain  ||| S:396 E:401 ||| NN
is  ||| S:401 E:404 ||| VBZ
common  ||| S:404 E:411 ||| JJ
in  ||| S:411 E:414 ||| IN
the  ||| S:414 E:418 ||| DT
general  ||| S:418 E:426 ||| JJ
population  ||| S:426 E:437 ||| NN
but  ||| S:437 E:441 ||| CC
may  ||| S:441 E:445 ||| MD
be  ||| S:445 E:448 ||| VB
related  ||| S:448 E:456 ||| VBN
to  ||| S:456 E:459 ||| TO
ankylosing  ||| S:459 E:470 ||| VB
spondylitis  ||| S:470 E:482 ||| NNS
( ||| S:482 E:483 ||| -LRB-
AS ||| S:483 E:485 ||| NNP
)  ||| S:485 E:487 ||| -RRB-
and  ||| S:487 E:491 ||| CC
other  ||| S:491 E:497 ||| JJ
axial  ||| S:497 E:503 ||| JJ
spondyloarthritis  ||| S:503 E:521 ||| NNS
( ||| S:521 E:522 ||| -LRB-
SpA ||| S:522 E:525 ||| NNP
)  ||| S:525 E:527 ||| -RRB-
in  ||| S:527 E:530 ||| IN
up  ||| S:530 E:533 ||| RB
to  ||| S:533 E:536 ||| TO
5 ||| S:536 E:537 ||| CD
%  ||| S:537 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
cases ||| S:542 E:547 ||| NNS
.  ||| S:547 E:549 ||| .
Mounting  ||| S:549 E:558 ||| VBG
evidence  ||| S:558 E:567 ||| NN
suggests  ||| S:567 E:576 ||| VBZ
that  ||| S:576 E:581 ||| DT
early  ||| S:581 E:587 ||| JJ
intervention  ||| S:587 E:600 ||| NN
leads  ||| S:600 E:606 ||| VBZ
to  ||| S:606 E:609 ||| TO
improve  ||| S:609 E:617 ||| VB
outcome  ||| S:617 E:625 ||| NN
both  ||| S:625 E:630 ||| CC
in  ||| S:630 E:633 ||| IN
RA  ||| S:633 E:636 ||| NNP
and  ||| S:636 E:640 ||| CC
SpA  ||| S:640 E:644 ||| NN
which  ||| S:644 E:650 ||| WDT
has  ||| S:650 E:654 ||| VBZ
important  ||| S:654 E:664 ||| JJ
socioeconomic  ||| S:664 E:678 ||| JJ
implications ||| S:678 E:690 ||| NNS
.  ||| S:690 E:692 ||| .
Early  ||| S:692 E:698 ||| RB
inflammatory  ||| S:698 E:711 ||| JJ
clinics  ||| S:711 E:719 ||| NNS
( ||| S:719 E:720 ||| -LRB-
EIC ||| S:720 E:723 ||| NNP
)  ||| S:723 E:725 ||| -RRB-
should  ||| S:725 E:732 ||| MD
therefore  ||| S:732 E:742 ||| RB
be  ||| S:742 E:745 ||| VB
considered  ||| S:745 E:756 ||| VBN
in  ||| S:756 E:759 ||| IN
every  ||| S:759 E:765 ||| DT
rheumatology  ||| S:765 E:778 ||| JJ
department  ||| S:778 E:789 ||| NN
to  ||| S:789 E:792 ||| TO
facilitate  ||| S:792 E:803 ||| VB
the  ||| S:803 E:807 ||| DT
early  ||| S:807 E:813 ||| JJ
assessment  ||| S:813 E:824 ||| NN
and  ||| S:824 E:828 ||| CC
diagnosis  ||| S:828 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
these  ||| S:841 E:847 ||| DT
patients  ||| S:847 E:856 ||| NNS
allowing  ||| S:856 E:865 ||| VBG
for  ||| S:865 E:869 ||| IN
prompt  ||| S:869 E:876 ||| JJ
and  ||| S:876 E:880 ||| CC
targeted  ||| S:880 E:889 ||| VBN
therapeutic  ||| S:889 E:901 ||| JJ
intervention ||| S:901 E:913 ||| NN
.  ||| S:913 E:915 ||| .
In  ||| S:915 E:918 ||| IN
addition  ||| S:918 E:927 ||| NN
the  ||| S:927 E:931 ||| DT
EICs  ||| S:931 E:936 ||| JJ
allow  ||| S:936 E:942 ||| NN
for  ||| S:942 E:946 ||| IN
a  ||| S:946 E:948 ||| DT
better  ||| S:948 E:955 ||| RBR
focused  ||| S:955 E:963 ||| VBN
follow-up  ||| S:963 E:973 ||| JJ
of  ||| S:973 E:976 ||| IN
these  ||| S:976 E:982 ||| DT
patients  ||| S:982 E:991 ||| NNS
in  ||| S:991 E:994 ||| IN
appropriate  ||| S:994 E:1006 ||| JJ
secondary  ||| S:1006 E:1016 ||| JJ
clinics ||| S:1016 E:1023 ||| NNS
.  ||| S:1023 E:1025 ||| .
Since  ||| S:1025 E:1031 ||| IN
the  ||| S:1031 E:1035 ||| DT
sustained  ||| S:1035 E:1045 ||| JJ
remission  ||| S:1045 E:1055 ||| NN
of  ||| S:1055 E:1058 ||| IN
inflammatory  ||| S:1058 E:1071 ||| JJ
and  ||| S:1071 E:1075 ||| CC
autoimmune  ||| S:1075 E:1086 ||| JJ
diseases  ||| S:1086 E:1095 ||| NNS
such  ||| S:1095 E:1100 ||| JJ
as  ||| S:1100 E:1103 ||| IN
RA  ||| S:1103 E:1106 ||| NNP
is  ||| S:1106 E:1109 ||| VBZ
highly  ||| S:1109 E:1116 ||| RB
dependent  ||| S:1116 E:1126 ||| JJ
on  ||| S:1126 E:1129 ||| IN
how  ||| S:1129 E:1133 ||| WRB
early  ||| S:1133 E:1139 ||| JJ
treatment  ||| S:1139 E:1149 ||| NN
is  ||| S:1149 E:1152 ||| VBZ
instigated  ||| S:1152 E:1163 ||| VBN
and  ||| S:1163 E:1167 ||| CC
its  ||| S:1167 E:1171 ||| PRP$
efficacy  ||| S:1171 E:1180 ||| NN
regularly  ||| S:1180 E:1190 ||| RB
assessed ||| S:1190 E:1198 ||| VBN
,  ||| S:1198 E:1200 ||| ,
there  ||| S:1200 E:1206 ||| EX
is  ||| S:1206 E:1209 ||| VBZ
legitimacy  ||| S:1209 E:1220 ||| VBN
for  ||| S:1220 E:1224 ||| IN
the  ||| S:1224 E:1228 ||| DT
EICs ||| S:1228 E:1232 ||| JJ
.  ||| S:1232 E:1234 ||| .
Furthermore ||| S:1234 E:1245 ||| RB
,  ||| S:1245 E:1247 ||| ,
there  ||| S:1247 E:1253 ||| EX
is  ||| S:1253 E:1256 ||| VBZ
a  ||| S:1256 E:1258 ||| DT
clear  ||| S:1258 E:1264 ||| JJ
research  ||| S:1264 E:1273 ||| NN
interest  ||| S:1273 E:1282 ||| NN
in  ||| S:1282 E:1285 ||| IN
building  ||| S:1285 E:1294 ||| VBG
early  ||| S:1294 E:1300 ||| JJ
inception  ||| S:1300 E:1310 ||| NN
cohorts  ||| S:1310 E:1318 ||| NNS
that  ||| S:1318 E:1323 ||| WDT
allow  ||| S:1323 E:1329 ||| VBP
for  ||| S:1329 E:1333 ||| IN
the  ||| S:1333 E:1337 ||| DT
characterization  ||| S:1337 E:1354 ||| NN
of  ||| S:1354 E:1357 ||| IN
the  ||| S:1357 E:1361 ||| DT
different  ||| S:1361 E:1371 ||| JJ
disease  ||| S:1371 E:1379 ||| NN
phenotypes ||| S:1379 E:1389 ||| NN
.  ||| S:1389 E:1391 ||| .
